<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420563</url>
  </required_header>
  <id_info>
    <org_study_id>PAL-ANGI 0601</org_study_id>
    <nct_id>NCT00420563</nct_id>
  </id_info>
  <brief_title>Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer</brief_title>
  <acronym>PALANGI-0601</acronym>
  <official_title>A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of the trial is to assess the free progression rate at 2 months for each group of
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate at 2 months</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate and objective response (RECIST) at 2, 4 and 6 months</measure>
    <time_frame>After 2, 4 and 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI scale v3.0</measure>
    <time_frame>During study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers</measure>
    <time_frame>the 2 first months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until death of the patient or until study analysis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time between the beginning of treatment and hospitalization due to progression or toxicity</measure>
    <time_frame>time of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MEGESTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLOPHOSPHAMIDE</intervention_name>
    <description>50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision</description>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEGESTROL</intervention_name>
    <description>320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision</description>
    <arm_group_label>MEGESTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18

          -  PS-WHO &lt; or = 1

          -  Histologically proven cancer

          -  No other therapeutic proposal

          -  Treatment can be orally taken

          -  Radiologic proof of evolutive character of the disease

          -  Effective contraception

        Exclusion Criteria:

          -  Hypercalcemia ( Ca &gt; 2.65 mmol/l)

          -  Breast cancer

          -  Thrombosis or pulmonary embolism

          -  Dysphagia, malabsorption

          -  Polynuclear neutrophil leukocytes &lt; 1000/mm3

          -  Treatment with Tegretol

          -  Active and uncontrolled infection

          -  Evolutive psychiatric disease

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PENEL Nicolas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Vincent</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional - Dermatology</name>
      <address>
        <city>Lille</city>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional - Oncology</name>
      <address>
        <city>Lille</city>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer, palliative treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

